• InterMune Inc., of Brisbane, Calif., reported preliminary fourth-quarter net sales of idiopathic pulmonary fibrosis drug Esbriet (pirfenidone) totaling about $2.8 million. The drug, which gained approval in Europe last year, has been launched in Germany, with about 612 patients prescribed since mid-September. InterMune plans to launch Esbriet in France, Spain and Italy in the second quarter and in the UK in October.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter